VIP
Also known as: Vasoactive Intestinal Peptide, Aviptadil
Popular For
Autoimmune conditions, CIRS/mold illness, inflammation
Key Facts: VIP
- Category
- Immune
- FDA Status
- Not FDA Approved
- Clinical Status
- Clinical Trials - Multiple indications
- Administration
- IV infusion, inhaled, or intranasal
- Typical Dose
- 50-100 mcg intranasal daily
- Frequency
- 1-2x daily, intranasal
- Evidence Level
- Human Trials
- Duration
- Variable by indication
Mechanism of Action
VIP binds to VPAC1 and VPAC2 receptors, triggering anti-inflammatory cascades. It relaxes smooth muscle, vasodilates, inhibits pro-inflammatory cytokines, and promotes regulatory T-cell function. Has broad immunomodulatory effects.
Research Summary
Clinical trials for COVID-19 ARDS showed promising results. Research demonstrates benefits in pulmonary arterial hypertension. Studies show potential for autoimmune conditions like rheumatoid arthritis and inflammatory bowel disease.
Dosing Information
Typical Dosingⓘ
Community experience
50-100 mcg intranasal daily
25-150 mcg daily
1-2x daily, intranasal
Vasoactive intestinal peptide. Used for CIRS/mold illness. Intranasal delivery. Requires proper diagnosis first.
Research Dosingⓘ
Scientific studies
Doses from clinical trials
Doses from Studies
50-100 mcg IV for acute conditions
Inhaled formulations studied
Duration
Variable by indication
Administration
IV infusion, inhaled, or intranasal
Timing & Administration
Best Time to Take
Morning or as directed
As prescribed
Food Recommendation
With or without food
Why This Timing?
VIP (Vasoactive Intestinal Peptide) affects multiple systems. Timing based on treatment goals.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Nausea and diarrhea
- ●Injection site reactions
- ●Headache
- ●Dizziness
- ●Facial flushing
- ●Blood pressure decrease
- ●Short-lived effects due to instability
References
Related Peptides
Peptides commonly compared with VIP or used in similar applications.
LL-37
Clinical TrialsA naturally occurring antimicrobial peptide and the only human cathelicidin. Part of the innate immune system with broad-spectrum antimicrobial activity.
ImmuneThymosin Alpha-1
Clinical TrialsA naturally occurring thymic peptide that enhances immune function. Approved in over 35 countries for hepatitis B/C and as an immune adjuvant.
ImmuneKPV
PreclinicalA tripeptide derived from alpha-melanocyte stimulating hormone (α-MSH). Known for potent anti-inflammatory effects, particularly in the gut.
ImmuneThymogen
Clinical TrialsA synthetic dipeptide (Glu-Trp) bioregulator derived from Thymalin, a thymus extract. One of Professor Khavinson's key immunomodulatory peptides, shown to stimulate T-lymphocyte development and normalize immune function. Has been used clinically in Russia for immune support.
ImmuneEnfuvirtide
FDAA peptide HIV fusion inhibitor that blocks viral entry into cells. First approved drug in the fusion inhibitor class.
ImmunePNC27
PreclinicalA chimeric anti-cancer peptide containing p53 residues 12-26 linked to a membrane-penetrating sequence. Selectively kills cancer cells by binding to HDM-2 expressed on cancer cell membranes, inducing membrane pore formation and necrosis while leaving normal cells unaffected.
ImmuneLooking for a trusted vendor?
Pro members get access to verified vendors with quality standards & exclusive discount codes.
Want updates on VIP research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.